Mark J Routbort
Overview
Explore the profile of Mark J Routbort including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
110
Citations
2367
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Marczyk V, Fazeli S, Dadu R, Busaidy N, Iyer P, Hu M, et al.
JCO Precis Oncol
. 2025 Feb;
9:e2400321.
PMID: 39983078
Purpose: Neurotrophic tropomyosin receptor kinase () fusions may act as an oncogenic driver in thyroid carcinomas. Given their low frequency, clinical, pathological, and molecular data on these patients and their...
2.
Yang R, Alvarez H, Lucas A, Roy-Chowdhuri S, Rashid A, Chen H, et al.
Cancer Genet
. 2024 Dec;
290-291():44-50.
PMID: 39700818
Impairment of DNA mismatch repair function in neoplasms can be assessed by DNA-based methods to assess for high microsatellite instability (MSI-High) or immunohistochemical (IHC) analysis to assess for deficiency of...
3.
Holla V, Kahle M, Kim S, Ronaghy A, Yang R, Patel K, et al.
JCO Precis Oncol
. 2024 Nov;
8:e2400419.
PMID: 39576951
Purpose: PD-1 inhibition is effective in patients with mismatch repair deficient (dMMR) solid tumors in a tumor-agnostic fashion. However, dMMR testing by immunohistochemistry (IHC) is not routinely performed across tumor...
4.
Loghavi S, Wei Q, Ravandi F, Quesada A, Routbort M, Hu S, et al.
Am J Hematol
. 2024 Jul;
99(10):1959-1968.
PMID: 39016111
Cytogenomic characterization is crucial for the classification and risk stratification of acute myeloid leukemia (AML), thereby facilitating therapeutic decision-making. We examined the clinical utility of optical genome mapping (OGM) in...
5.
Zheng L, Luthra R, Alvarez H, San Lucas F, Duose D, Wistuba I, et al.
Cancers (Basel)
. 2024 Jan;
16(1).
PMID: 38201434
Epidermal growth factor receptor variant III (EGFRvIII, the deletion of exons 2-7) is a recurrent intragenic .E1E8 fusion that occurs in high-grade gliomas. The presence of EGFRvIII in other solid...
6.
Yin C, Tam W, Walker S, Kaur A, Ouseph M, Xie W, et al.
Haematologica
. 2023 Nov;
109(6):1825-1835.
PMID: 37981812
STAT5B has been reported as a recurrent mutation in myeloid neoplasms with eosinophilia, but its overall frequency and importance across a spectrum of myeloid neoplasms are largely unknown. We conducted...
7.
Diks J, Tang Z, Altan M, Anderson S, Chen H, Rashid A, et al.
Cancer Cytopathol
. 2023 Sep;
132(1):41-49.
PMID: 37747438
Background: Genomic profiling is needed to identify actionable alterations in non-small cell lung cancer (NSCLC). Panel-based testing such as next-generation sequencing (NGS) is often preferred to interrogate multiple alterations simultaneously....
8.
Chen H, Ding Q, Khazai L, Zhao L, Damodaran S, Litton J, et al.
Ther Adv Med Oncol
. 2023 Aug;
15:17588359231189422.
PMID: 37547448
Background: Recent advances have been made in targeting the phosphoinositide 3-kinase pathway in breast cancer. Phosphatase and tensin homolog (PTEN) is a key component of that pathway. Objective: To understand...
9.
Jelloul F, Routbort M, DiNardo C, Bueso-Ramos C, Kanagal-Shamanna R, Thakral B, et al.
Am J Hematol
. 2023 May;
98(8):E193-E196.
PMID: 37154083
No abstract available.
10.
Hong L, Aminu M, Li S, Lu X, Petranovic M, Saad M, et al.
Nat Commun
. 2023 Feb;
14(1):695.
PMID: 36755027
The role of combination chemotherapy with immune checkpoint inhibitors (ICI) (ICI-chemo) over ICI monotherapy (ICI-mono) in non-small cell lung cancer (NSCLC) remains underexplored. In this retrospective study of 1133 NSCLC...